24 Chapter 2 Table 1. Continued Preoperative characteristics Total (n=75) Volume displacement (n=56) Volume replacement (n=19) P-value Caudomedial 1 (7.7) 1 (10) 0 (0) Medial 4 (30.8) 4 (40) 0 (0) Neoadjuvant chemotherapy 18 (24.0) 12 (21.4) 6 (31.6) 0.370 Neoadjuvant hormone therapy 3 (4.0) 3 (5.4) 0 (0.0) 0.567 Contralateral symmetrization 21 (28.0) 20 (35.7) 1 (5.3) 0.011 Surgical characteristics Total (n=75) Volume displacement (n=56) Volume replacement (n=19) P-value Operative time, min 108 (90-129) 105 (89-126) 117 (103-136) 0.061 Weight resected specimen, gram 84 (46-102) 80 (45-94) 98 (46-135) 0.469 Reduction weight, gram - 147 (45-305) - Sentinel node 67 (89.3) 51 (91) 16 (84) 0.360 Adjuvant radiotherapy 70 (93.3) 52 (95) 18 (95) 1.000 Adjuvant chemotherapy 20 (26.7) 17 (30) 3 (16) 0.249 Adjuvant hormone therapy 40 (53.3) 30 (54) 10 (53) 1.000 Data are n (%) or median (IQR). Significant P-values are denoted in italic. ASA indicates American Association of Anesthesiologists; BMI, body mass index; DCIS, ductal carcinoma in situ. BREAST-Q questionnaire Fifty-two patients completed the BREAST-Q questionnaire. Of these patients, only 34 (65.4%) filled out the domain ‘sexual well-being’. The domains ‘satisfaction with breasts’, ‘satisfaction with information about the surgery’ and ‘satisfaction with plastic surgeon’ were filled out by 51 patients (98.1%). Al other domains were fully completed. The median time from surgery until completion of the BREAST-Q was 28 months (IQR: 16-39 months). The BREAST-Q scale scores were compared between OPS with volume replacement and volume displacement. Women who underwent volume displacement techniques reported significantly higher scores for ‘physical well-
RkJQdWJsaXNoZXIy MTk4NDMw